David A. Siegel Allogene Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

$46.1 Billion
Q2 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 1,767,400 shares of ALLO stock, worth $2.28 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,767,400

Previous 2,200,800 19.69%

Holding current value

$2.28 Million

Previous $3.21 Million 37.85%

% of portfolio

0.0%

Previous 0.01%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$0.95 - $1.7 $411,730 - $736,780	-433,400 Reduced 19.69%	1,767,400 $2 Million
Q1 2025 May 15, 2025	SELL	$1.4 - $2.84 $701,960 - $1.42 Million	-501,400 Reduced 18.56%	2,200,800 $3.21 Million
Q4 2024 Feb 14, 2025	BUY	$1.84 - $3.22 $536,912 - $939,596	291,800 Added 12.11%	2,702,200 $5.76 Million
Q3 2024 Nov 14, 2024	BUY	$2.08 - $3.5 $349,232 - $587,650	167,900 Added 7.49%	2,410,400 $6.75 Million
Q2 2024 Aug 14, 2024	BUY	$2.23 - $4.38 $2.03 Million - $3.99 Million	911,400 Added 68.47%	2,242,500 $5.23 Million
Q1 2024 May 15, 2024	BUY	$2.92 - $5.63 $155,928 - $300,642	53,400 Added 4.18%	1,331,100 $5.95 Million
Q4 2023 Feb 14, 2024	BUY	$2.28 - $3.5 $685,139 - $1.05 Million	300,500 Added 30.75%	1,277,700 $4.1 Million
Q3 2023 Nov 14, 2023	SELL	$3.17 - $5.96 $752,875 - $1.42 Million	-237,500 Reduced 19.55%	977,200 $3.1 Million
Q2 2023 Aug 14, 2023	SELL	$4.53 - $6.74 $362,853 - $539,874	-80,100 Reduced 6.19%	1,214,700 $6.04 Million
Q1 2023 May 15, 2023	BUY	$4.92 - $8.21 $1.65 Million - $2.75 Million	334,400 Added 34.82%	1,294,800 $6.4 Million
Q4 2022 Feb 14, 2023	BUY	$5.62 - $11.11 $4.15 Million - $8.2 Million	737,900 Added 331.64%	960,400 $6.04 Million
Q3 2022 Nov 14, 2022	BUY	$10.32 - $17.28 $928,800 - $1.56 Million	90,000 Added 67.92%	222,500 $2.4 Million
Q2 2022 Aug 15, 2022	SELL	$6.78 - $12.28 $678,000 - $1.23 Million	-100,000 Reduced 43.01%	132,500 $1.51 Million
Q1 2022 May 16, 2022	BUY	$7.65 - $15.29 $1.78 Million - $3.55 Million	232,500 New	232,500 $2.12 Million
Q3 2021 Nov 15, 2021	SELL	$21.01 - $27.64 $1.42 Million - $1.87 Million	-67,800 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$23.49 - $35.8 $8.13 Million - $12.4 Million	-346,300 Reduced 83.63%	67,800 $1.77 Million
Q1 2021 May 17, 2021	BUY	$25.79 - $39.02 $1.61 Million - $2.43 Million	62,300 Added 17.71%	414,100 $14.6 Million
Q4 2020 Feb 16, 2021	BUY	$25.24 - $43.45 $360,932 - $621,335	14,300 Added 4.24%	351,800 $8.88 Million
Q3 2020 Nov 16, 2020	BUY	$32.38 - $44.96 $9.89 Million - $13.7 Million	305,300 Added 948.14%	337,500 $12.7 Million
Q2 2020 Aug 14, 2020	BUY	$18.39 - $54.04 $592,158 - $1.74 Million	32,200 New	32,200 $1.38 Million

Others Institutions Holding ALLO

# of Institutions

169

Shares Held

162M

Call Options Held

146K

Put Options Held

97.1K

View Full List

About Allogene Therapeutics, Inc.

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $186M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

More about ALLO

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account